technology

Description:

Bridge-It^® Assay Platform Technology
	Mediomics' novel DNA-binding protein assay design utilizes a two fluorophore system (a fluorophore donor and a fluorophore acceptor) in which the DNA fragment containing the binding site for the target protein is ............. detail >>

Pincer^TMAssay Platform Technology
	Mediomics’ pincer^TMassay contains two PINCERs (binders) which recognize two different epitopes of the target. Short signaling molecules containing the matching pair of fluorophores are attached to the two ............ detail >>

Exclusive Patent License:

Mediomics, LLC holds an exclusive, worldwide license (with right to sublicense) for all possible commercial product applications covered by the claims of the issued and pending patents and patent applications invented in Dr. Tomasz Heyduk, Dr. Yie-Hwa Chang and Dr. David Waisman’s laboratories. This exclusive licensing agreement also provides to Mediomics an exclusive commercial license for all patents relating to the exclusively licensed patents, including any follow-on patents. Currently, Mediomics holds exclusive license for over 40 issued patents and pending patent applications (including any and all related patent filings).

Trademarks:

The registered trademark, Bridge-It^®, is owned by Mediomics. A trademark registration application for Mediomics trademark Pincers^TMis currently pending at the US-Patent and Trademark Office.